AKT1 Primary Antibody
The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene.
Purified antibody in PBS with 0.05% sodium azide
4°C; -20°C for long term storage
Figure 1: Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Figure 2:Western blot analysis using AKT1 mAb against human AKT1 (AA: 1-150) recombinant protein. (Expected MW is 43.6 kDa)
Figure 3:Western blot analysis using AKT1 mAb against HEK293 (1) and AKT1 (AA: 1-150)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 4:Western blot analysis using AKT1 mouse mAb against A549 (1), MCF-7 (2), Hela (3), COS7 (4), C6 (5), and HL-60 (6) cell lysate.
Figure 5:Flow cytometric analysis of Hela cells using AKT1 mouse mAb (green) and negative control (red).
Figure 6:Immunohistochemical analysis of paraffin-embedded esophageal cancer tissues using AKT1 mouse mAb with DAB staining.
Figure 7:Immunohistochemical analysis of paraffin-embedded endometrial cancer tissues using AKT1 mouse mAb with DAB staining.
For Research Use Only. Not for use in diagnostic procedures.